Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial - Wu, Yi-Long; Lu, Shun; Cheng, Ying; Zhou, Caicun; Wang, Jie; Mok, Tony; Zhang, Li; Tu, Hai-Yan; Wu, Lin; Feng, Jifeng; Zhang, Yiping; Luft, Alexander Valerievich; et al. (Journal of thoracic oncology, 2019)
Keywords: Chinese population; Nivolumab; NSCLC; Phase III clinical study; Chinese population; NSCLC; Nivolumab; Phase III clinical study